相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
相关阅读
AI 赋能培养基定制开发:CHO 培养基是如何实现产量提升Cytoscape 教程来了!快速实现顶刊同款通路网络图五大应用案例:Mustang Q 膜层析应用全解析1 个小工具,一次性搞定流程图、质粒图谱和信号通路图- 详细信息
- 文献和实验
- 技术资料
- 保存条件:
Powder: -20°C, 3 years; 4°C, 2 years.In solvent: -80°C, 6 months; -20°C, 1 month.
- 英文名:
HTL0014242
- 库存:
货期:1-2天
- 供应商:
MedChemExpress LLC
- CAS号:
1644645-32-8
- 规格:
10 mM * 1 mL/5 mg/10 mg
| 规格: | 10 mM * 1 mL | 产品价格: | ¥2310.0 |
|---|---|---|---|
| 规格: | 5 mg | 产品价格: | ¥2100.0 |
| 规格: | 10 mg | 产品价格: | ¥3500.0 |
MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
HTL14242
CAS No. : 1644645-32-8
MCE 国际站:HTL14242
产品活性:HTL14242 (HTL0014242) 是一种高级、口服活性强的 mGlu5 负变构调制器,其 pKi 和 pIC50 值分别为 9.3 和 9.2。HTL14242 可用于帕金森病的研究。
研究领域:GPCR/G Protein | Neuronal Signaling
作用靶点:mGluR
In Vitro: HTL14242 is stable in rat plasma, inactive at the hERG ion-channel, and has a clean profile in vitro assays of cytotoxicity in HepG2 cells, the TC50 is >90 μM.
In Vivo: HTL14242 (oral administration; 1, 3, or 10 mg/kg; sacrificed 1 h postdose) emonstrates an excellent, dose-dependent occupancy of mGlu5 receptors from an oral dose, with an estimated ED50 of 0.3 mg/kg.
HTL14242 (oral administration; 1 mg/ml) exhibits an oral PK Profile, the t1/2, AUCinf and F% are 6.5 hours, 3946 ng/h/mL and 80%, respectively in dog.
相关产品:Clinical Compound Library Plus | Bioactive Compound Library Plus | GPCR/G Protein Compound Library | Neuronal Signaling Compound Library | Clinical Compound Library | Orally Active Compound Library | Neurotransmitter Receptor Compound Library | Chemical Probe Library | Neuroprotective Compound Library | Anti-Parkinson's Disease Compound Library | Neurodegenerative Disease-related Compound Library | Antidepressant Compound Library | Heterocyclic Compound Library | Membrane Protein-targeted Compound Library | Membrane Receptor-targeted Compound Library | Highly Selective Inhibitors Library | L-Glutamine | LY341495 | Ro 67-7476 | Xanthurenic acid | DHPG | Eglumegad | MPEP Hydrochloride | MTEP hydrochloride | CHPG sodium salt | CTEP | JNJ16259685 | (RS)-MCPG | LY2794193 | LY367385 hydrochloride | LY404039 | O-Phospho-L-serine | Mavoglurant | Dipraglurant | NPS 2390 | MMPIP hydrochloride | MSOP | RO0711401 | AMN082 | Basimglurant | Foliglurax monohydrochloride | JNJ-40411813
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验基因测不准、PDX 等不及?患者来源类器官(PDTO) 个体化试药,肿瘤科可落地 SCI 方案
therapy for KRAS-mutant pancreatic cancer: synergistic MEK/mTOR inhibition and predictive chemotherapy responses 期刊:Frontiers in Immunology(IF=8.7,2026) 研究内容: ➤耐药表型初筛:对 32 种临床药物(含化疗及靶向药物)进行梯度筛选,发现 Trametinib 单药仅短期抑制 ERK,mTOR 持续活化造成肿瘤耐药; ➤联合药效分层验证:设置
技术资料暂无技术资料 索取技术资料


















